Skip to main content

Dana-Farber Research Publication 4.1.2022

View Archive Newsletters

April 1, 2022

This twice-monthly newsletter highlights the research endeavors at Dana-Farber Cancer Institute, noting recently published papers available from PubMed where Dana-Farber faculty are listed as first or senior authors.


How I Treat Neurologic Complications in Patients with Lymphoid Cancer

Nayak L, Batchelor TT

Neurologic complications of lymphoid cancer can be challenging to recognize and treat. The nervous system can be affected directly by hematogenous or local spread of lymphoma. Indirect neurologic effects of lymphoma include paraneoplastic syndromes and vascular complications. Lymphoma treatments can also cause neurologic complications. Early identification and treatment are crucial to stabilize or reverse neurologic deficits, prevent further nervous system injury, and optimize overall oncologic therapy. This article provides an overview of the different neurologic complications of lymphoma and its treatments, in addition to presenting case studies that emphasize commonly encountered clinical scenarios.



mpact of Diagnostic Genetics on Remission MRD and Transplantation Outcomes in Older AML Patients

Murdock HM, Kim HT, Tsai HK, Ho VT, Koreth J, Soiffer RJ, Ritz J, Lindsley RC, Gibson CJ

Older patients with acute myeloid leukemia (AML) have high relapse risk and poor survival after allogeneic hematopoietic cell transplantation (HCT). Younger patients may receive myeloablative conditioning to mitigate relapse risk associated with high-risk genetics or measurable residual disease (MRD), but older adults typically receive reduced-intensity conditioning (RIC) to limit toxicity. To identify factors that drive HCT outcomes in older patients, we performed targeted mutational analysis (VAF 2%) on diagnostic samples from 295 AML patients age 60 or older who underwent HCT in first complete remission, 91% of whom received RIC, and targeted duplex sequencing at the time of remission in 192 patients. In a multivariable model for leukemia-free survival (LFS) including baseline genetic and clinical variables, we defined patients with low (3-year LFS 85%), intermediate (55%), high (35%), and very high risk (7%). Prior to HCT, 79.7% of patients had persistent baseline mutations, including 18.3% with only DNMT3A or TET2 mutations (DT) and 61.4% with other mutations (MRDpositive). In univariable analysis, MRD-positivity was associated with increased relapse and inferior LFS compared with DT and MRDnegative patients. However, in a multivariable model accounting for baseline risk, MRD-positivity had no independent impact on LFS, likely due to its significant association with diagnostic genetic characteristics including MDS-associated gene mutations, TP53 mutations, and high-risk karyotype. In conclusion, molecular associations with MRD positivity and transplant outcomes in older AML patients are driven primarily by baseline genetics, and not by mutations present in remission. In this group of patients, where high-intensity conditioning carries substantial risk of toxicity, alternative approaches to mitigating MRD-associated relapse risk are required.


Cancer Discovery

EP300 Selectively Controls the Enhancer Landscape of MYCN-Amplified Neuroblastoma

Durbin AD, Wang T, Wimalasena VK, Zimmerman MW, Li D, Dharia NV, Mariani L, Park PMC, Sigua LH, Morita K, Conway AS, Robichaud AL, Perez-Atayde AR, Bulyk ML, Stegmaier K, Look AT, Qi J

Gene expression is regulated by promoters and enhancers marked by histone H3 lysine 27 acetylation (H3K27ac), which is established by the paralogous histone acetyltransferases (HAT) EP300 and CBP. These enzymes display overlapping regulatory roles in untransformed cells, but less characterized roles in cancer cells. We demonstrate that the majority of high-risk pediatric neuroblastoma (NB) depends on EP300, whereas CBP has a limited role. EP300 controls enhancer acetylation by interacting with TFAP2?, a transcription factor member of the lineage-defining transcriptional core regulatory circuitry (CRC) in NB. To disrupt EP300, we developed a proteolysis-targeting chimera (PROTAC) compound termed "JQAD1" that selectively targets EP300 for degradation. JQAD1 treatment causes loss of H3K27ac at CRC enhancers and rapid NB apoptosis, with limited toxicity to untransformed cells where CBP may compensate. Furthermore, JQAD1 activity is critically determined by cereblon (CRBN) expression across NB cells.

SIGNIFICANCE: EP300, but not CBP, controls oncogenic CRC-driven transcription in high-risk NB by binding TFAP2?. We developed JQAD1, a CRBN-dependent PROTAC degrader with preferential activity against EP300 and demonstrated its activity in NB. JQAD1 has limited toxicity to untransformed cells and is effective in vivo in a CRBN-dependent manner. This article is highlighted in the In This Issue feature, p. 587.



Surveillance Imaging in Individuals at High Risk for Pancreatic Cancer: Not a Ceiling, but Rather a Floor Upon Which to Build

Rosenthal MH, Wolpin BM, Yurgelun MB

Pancreatic cancer (PC) is the third leading cause of cancer-related death in the United States and the European Union. More than 80% of patients who develop pancreatic cancer have locally advanced or metastatic disease at diagnosis and experience median overall survival times of . Identification of early-stage PC and high-risk PC precursors is a necessary step in reducing mortality from this malignancy. An expert panel convened by the International Cancer of the Pancreas Screening (CAPS) Consortium has stated that the goal of PC surveillance should be identification and resection of PC precursor lesions with high-grade dysplasia or PCs that are confined to the pancreas, ?2 cm in maximal diameter, and without lymph node involvement (AJCC 7th Edition, pT1N0M0). Initial attempts at imaging-based PC surveillance in high-risk individuals (HRIs) with genetic or familial PC predisposition demonstrated the feasibility of annual magnetic resonance imaging (MRI) and endoscopic ultrasound (EUS) to identify asymptomatic individuals with high-grade precursor lesions. Although randomized data on PC surveillance remain lacking, recent prospective studies have suggested tumor downstaging from MRI- and EUS-based PC surveillance and longer survival times compared with historical data, leading to clinical practice guidelines that recommend surveillance be considered for certain HRIs.


Journal of Clinical Oncology

Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update

Meyerhardt JA

PURPOSE: To develop recommendations for adjuvant therapy for patients with resected stage II colon cancer.

METHODS: ASCO convened an Expert Panel to conduct a systematic review of relevant studies and develop recommendations for clinical practice.

RESULTS: Twenty-one observational studies and six randomized controlled trials met the systematic review inclusion criteria.

RECOMMENDATIONS: Adjuvant chemotherapy (ACT) is not routinely recommended for patients with stage II colon cancer who are not in a high-risk subgroup. Patients with T4 tumors are at higher risk of recurrence and should be offered ACT, whereas patients with other high-risk factors, including sampling of fewer than 12 lymph nodes in the surgical specimen, perineural or lymphovascular invasion, poorly or undifferentiated tumor grade, intestinal obstruction, tumor perforation, or grade BD3 tumor budding, may be offered ACT. The addition of oxaliplatin to fluoropyrimidine-based ACT is not routinely recommended, but may be offered as a result of shared decision making. Patients with mismatch repair deficiency/microsatellite instability tumors should not be routinely offered ACT; if the combination of mismatch repair deficiency/microsatellite instability and high-risk factors results in a decision to offer ACT, oxaliplatin-containing chemotherapy is recommended. Duration of oxaliplatin-containing chemotherapy is also addressed, with recommendations for 3 or 6 months of treatment with capecitabine and oxaliplatin or fluorouracil, leucovorin, and oxaliplatin, with decision making informed by key evidence of 5-year disease-free survival in each treatment subgroup and the rate of adverse events, including peripheral neuropathy.Additional information is available at


Journal of Clinical Oncology

Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP

Sweeney CJ

PURPOSE: We previously reported that enzalutamide improved overall survival when added to standard of care in metastatic, hormone-sensitive prostate cancer. Here, we report its effects on aspects of health-related quality of life (HRQL).

METHODS:HRQL was assessed with the European Organisation for Research and Treatment of Cancer core quality-of-life questionnaire and QLM-PR25 at weeks 0, 4, 12, and then every 12 weeks until progression. Scores from week 4 to 156 were analyzed with repeated measures modeling to calculate group means and differences. Deterioration-free survival was from random assignment until the earliest of death, clinical progression, discontinuation of study treatment, or a worsening of 10 points or more from baseline in fatigue, physical function, cognitive function, or overall health and quality of life (OHQL). HRQL scores range from 0 (lowest possible) to 100 (highest possible).

RESULTS: Twenty-one observational studies and six randomized controlled trials met the systematic review inclusion criteria.

RECOMMENDATIONS: HRQL was assessed in 1,042 of 1,125 participants (93%). Differences in means favored control over enzalutamide for fatigue (5.2, 95% CI, 3.6 to 6.9; P < .001), cognitive function (4.0, 95% CI, 2.5 to 5.5; P < .001), and physical function (2.6, 95% CI, 1.3 to 3.9; P < .001), but not OHQL (1.2, 95% CI, -0.2 to 2.7; P = .1). Deterioration-free survival rates at 3 years, and log-rank P values comparing the whole distributions, favored enzalutamide over control for OHQL (31% v 17%; P < .0001), cognitive function (31% v 20%; P = .001), and physical function (31% v 22%; P < .001), but not fatigue (24% v 18%; P = .16). The effects of enzalutamide on HRQL were independent of baseline characteristics.

CONCLUSION: Enzalutamide was associated with worsening of self-reported fatigue, cognitive function, and physical function, but not OHQL. Enzalutamide was associated with improved deterioration-free survival for OHQL, physical function, and cognitive function because delays in disease progression outweighed early deteriorations in these aspects of HRQL.


Journal of Clinical Oncology

Isn't Androgen Deprivation Enough? Optimal Treatment for Newly Diagnosed Metastatic Prostate Cancer

Morgans AK, Beltran H

The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice.


Journal of Clinical Oncology

Reply to T. Olivier et al

Hodi FS

We appreciate the thoughtful comments from Drs Olivier and Prasad regarding the primary manuscript and editorial describing the CheckMate 067 6.5-year follow-up data. In general, we agree that there is no single standard of care for all patients with metastatic melanoma. The choice of primary therapy is one that requires careful balancing of antitumor activity with toxicities and is best decided through transparent discussions between patients and oncology clinicians. We also concur that such decisions are best informed by randomized trials and that only data from such trials would address the important point made regarding combination checkpoint blockade or monotherapy. However, the choice of a control arm for such a trial is challenging given the dynamic nature of available therapies for metastatic melanoma. As noted in the editorial, given the recently published RELATIVITY-047 results,4 which demonstrated superior progression-free survival with nivolumab plus relatlimab (a LAG-3–blocking antibody) versus nivolumab monotherapy, an ethical question would emerge when comparing nivolumab plus ipilimumab with nivolumab monotherapy.


Journal of Clinical Oncology

Therapy for Muscle-Invasive Urothelial Carcinoma: Controversies and Dilemmas

Sonpavde GP, Mouw KW, Mossanen M

The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice.


Journal of the National Cancer Institute

Survival in Young-Onset Metastatic Colorectal Cancer: Findings from Cancer and Leukemia Group B (Alliance)/SWOG 80405

Lipsyc-Sharf M, Ma C, McCleary NJ, Mayer RJ, Meyerhardt JA, Ng K

Background: The incidence of young-onset colorectal cancer (yoCRC) is increasing. It is unknown if there are survival differences between young and older patients with metastatic colorectal cancer (mCRC).

METHODS: We studied the association of age with survival in 2326 mCRC patients enrolled in the Cancer and Leukemia Group B and SWOG 80405 trial, a multicenter, randomized trial of first-line chemotherapy plus biologics. The primary and secondary outcomes of this study were overall survival (OS) and progression-free survival (PFS), respectively, which were assessed by Kaplan-Meier method and compared among younger vs older patients with the log-rank test. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated based on Cox proportional hazards modeling, adjusting for known prognostic variables. All statistical tests were 2-sided.

RESULTS:Of 2326 eligible subjects, 514 (22.1%) were younger than age 50 years at study entry (yoCRC cohort). The median age of yoCRC patients was 44.3 vs 62.5 years in patients aged 50 years and older. There was no statistically significant difference in OS between yoCRC vs older-onset patients (median = 27.07 vs 26.12 months; adjusted HR = 0.98, 95% CI = 0.88 to 1.10; P = .78). The median PFS was also similar in yoCRC vs older patients (10.87 vs 10.55 months) with an adjusted hazard ratio of 1.02 (95% CI = 0.92 to 1.13; P = .67). Patients younger than age 35 years had the shortest OS with median OS of 21.95 vs 26.12 months in older-onset patients with an adjusted hazard ratio of 1.08 (95% CI = 0.81 to 1.44; Ptrend = .93).

CONCLUSION:In this large study of mCRC patients, there were no statistically significant differences in survival between patients with yoCRC and CRC patients aged 50 years and older.


Lancet Oncology

Isatuximab Plus Pomalidomide and Low-Dose Dexamethasone Versus Pomalidomide and Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma (ICARIA-MM): Follow-Up Analysis of a Randomised, Phase 3 Study

Richardson PG, Anderson KC

Background: The primary analysis of the ICARIA-MM study showed significant improvement in progression-free survival with addition of isatuximab to pomalidomide-dexamethasone in relapsed and refractory multiple myeloma. Here, we report a prespecified updated overall survival analysis at 24 months after the primary analysis.

METHODS: In this randomised, multicentre, open-label, phase 3 study adult patients (aged 18 years) with relapsed and refractory multiple myeloma who had received at least two previous lines of therapy, including lenalidomide and a proteasome inhibitor, and had an Eastern Cooperative Oncology Group performance status of 0-2 were recruited from 102 hospitals in 24 countries across Europe, North America, and the Asia-Pacific regions. Patients were excluded if they had anti-CD38 refractory disease or previously received pomalidomide. Patients were randomly assigned (1:1), using an interactive response technology with permuted blocked randomisation (block size of four) and stratified by number of previous treatment lines (2-3 vs >3) and aged (

Wen PY

We thank Osman Sütcüo?lu and colleagues for their response to our Article on treatment with dabrafenib–trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma. Their Correspondence raises two points for discussion: the difference between median progression-free survival and median overall survival and the post-progression therapies in patients with gliomas, including glioblastoma after dabrafenib–trametinib treatment.

As shown in our Article's appendix, notably the cohort of patients with high-grade glioma was separated into two subsets—those with disease that progressed quickly, often at or before the first assessment after baseline, and those with good durability of response, with only a few patients falling between these groups. These subsets provide insight into the difference between median progression-free survival and median overall survival, since the median describes the average patient, who might fall between these two subsets. Additionally, the upper limit of the 95% CI for median progression-free survival in patients with glioblastoma is 13·7 months, indicating a high degree of variation in the median estimate of 2·8 months and reflecting the subgroup of patients with longer progression-free survival.


Molecular Cell

MLL::AF9 Degradation Induces Rapid Changes in Transcriptional Elongation and Subsequent Loss of an Active Chromatin Landscape

Olsen SN, Godfrey L, Healy JP, Choi YA, Kai Y, Hatton C, Perner F, Haarer EL, Armstrong SA

MLL rearrangements produce fusion oncoproteins that drive leukemia development, but the direct effects of MLL-fusion inactivation remain poorly defined. We designed models with degradable MLL::AF9 where treatment with small molecules induces rapid degradation. We leveraged the kinetics of this system to identify a core subset of MLL::AF9 target genes where MLL::AF9 degradation induces changes in transcriptional elongation within 15 minutes. MLL::AF9 degradation subsequently causes loss of a transcriptionally active chromatin landscape. We used this insight to assess the effectiveness of small molecules that target members of the MLL::AF9 multiprotein complex, specifically DOT1L and MENIN. Combined DOT1L/MENIN inhibition resembles MLL::AF9 degradation, whereas single-agent treatment has more modest effects on MLL::AF9 occupancy and gene expression. Our data show that MLL::AF9 degradation leads to decreases in transcriptional elongation prior to changes in chromatin landscape at select loci and that combined inhibition of chromatin complexes releases the MLL::AF9 oncoprotein from chromatin globally.


Molecular Cell

Regulation of GTPase Function by Autophosphorylation

Johnson CW, Seo HS, Yang MH, Geffken EA, Lakhani J, Song K, Bashyal P, Popow O, Paulo JA, Liu A, Dhe-Paganon S, Haigis KM

A unifying feature of the RAS superfamily is a conserved GTPase cycle by which these proteins transition between active and inactive states. We demonstrate that autophosphorylation of some GTPases is an intrinsic regulatory mechanism that reduces nucleotide hydrolysis and enhances nucleotide exchange, altering the on/off switch that forms the basis for their signaling functions. Using X-ray crystallography, nuclear magnetic resonance spectroscopy, binding assays, and molecular dynamics on autophosphorylated mutants of H-RAS and K-RAS, we show that phosphoryl transfer from GTP requires dynamic movement of the switch II region and that autophosphorylation promotes nucleotide exchange by opening the active site and extracting the stabilizing Mg2+. Finally, we demonstrate that autophosphorylated K-RAS exhibits altered effector interactions, including a reduced affinity for RAF proteins in mammalian cells. Thus, autophosphorylation leads to altered active site dynamics and effector interaction properties, creating a pool of GTPases that are functionally distinct from their non-phosphorylated counterparts.



Silent Mutations Reveal Therapeutic Vulnerability in RAS Q61 Cancers

Kobayashi Y, Chhoeu C, Li J, Wei Z, Hong F, Bahcall M, Gokhale PC, Jänne PA

RAS family members are the most frequently mutated oncogenes in human cancers. Although KRAS(G12C)-specific inhibitors show clinical activity in patients with cancer1-3, there are no direct inhibitors of NRAS, HRAS or non-G12C KRAS variants. Here we uncover the requirement of the silent KRASG60G mutation for cells to produce a functional KRAS(Q61K). In the absence of this G60G mutation in KRASQ61K, a cryptic splice donor site is formed, promoting alternative splicing and premature protein termination. A G60G silent mutation eliminates the splice donor site, yielding a functional KRAS(Q61K) variant. We detected a concordance of KRASQ61K and a G60G/A59A silent mutation in three independent pan-cancer cohorts. The region around RAS Q61 is enriched in exonic splicing enhancer (ESE) motifs and we designed mutant-specific oligonucleotides to interfere with ESE-mediated splicing, rendering the RAS(Q61) protein non-functional in a mutant-selective manner. The induction of aberrant splicing by antisense oligonucleotides demonstrated therapeutic effects in vitro and in vivo. By studying the splicing necessary for a functional KRAS(Q61K), we uncover a mutant-selective treatment strategy for RASQ61 cancer and expose a mutant-specific vulnerability, which could potentially be exploited for therapy in other genetic contexts.


New England Journal of Medicine

Tumor-Infiltrating T Cells - A Portrait


Immunotherapies have transformed the management of advanced cancers, yet many patients do not receive long-lasting clinical benefit from these agents. T cells are the primary mediators of antitumor immunity and play a central role in the response to immunotherapies. Despite substantial therapeutic advances, we do not fully understand the phenotype and function of tumor-infiltrating T cells in different types of cancer and how they affect clinical outcomes.



A Functional Subdivision within the Somatosensory System and its Implications for Pain Research

Ma Q

Somatosensory afferents are traditionally classified by soma size, myelination, and their response specificity to external and internal stimuli. Here, we propose the functional subdivision of the nociceptive somatosensory system into two branches. The exteroceptive branch detects external threats and drives reflexive-defensive reactions to prevent or limit injury. The interoceptive branch senses the disruption of body integrity, produces tonic pain with strong aversive emotional components, and drives self-caring responses toward to the injured region to reduce suffering. The central thesis behind this functional subdivision comes from a reflection on the dilemma faced by the pain research field, namely, the use of reflexive-defensive behaviors as surrogate assays for interoceptive tonic pain. The interpretation of these assays is now being challenged by the discovery of distinct but interwoven circuits that drive exteroceptive versus interoceptive types of behaviors, with the conflation of these two components contributing partially to the poor translation of therapies from preclinical studies.


Advances in Radiation Oncology

Dosimetric Modeling of Lymphopenia in Patients with Metastatic Cancer Receiving Palliative Radiation and PD-1 Immune Checkpoint Inhibitors

Qian JM, Akama-Garren E, Shin J, Gunasti L, Bang A, Grassberger C, Schoenfeld JD


American Journal of Hematology

A Multicenter, Retrospective Study of Accelerated Venetoclax Ramp-Up in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

Davids MS, Crombie JL


American Journal of Hematology

A Multicenter, Retrospective Study of Accelerated Venetoclax Ramp-Up in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

Davids MS, Crombie JL


American Journal of Medical Quality

Early Findings on the Use of Clinical Pathways for Management of Unwarranted Variation in Cancer Care

Jackman DM, Foster E, Hamilton JM, Tremonti C, Bunnell CA, Stuver SO, Jacobson JO


BJUI Compass

FGFR2/3 Genomic Alterations and Response to Enfortumab Vedotin in Metastatic Urothelial Carcinoma

Adib E, El Zarif T, Freeman D, Curran C, Akl E, Nassar AH, Ravi P, Mantia C, Kwiatkowski DJ, Choueiri TK, Sonpavde G


Blood Advances

A New Role for the SRC Family Kinase HCK as a Driver of SYK Activation in MYD88 Mutated Lymphomas

Munshi M, Liu X, Kofides A, Tsakmaklis N, Guerrera ML, Hunter ZR, Patterson CJ, Canning AG, Meid KE, Branagan AR, Flynn C, Sarosiek S, Castillo JJ, Wang J, Buhrlage S, Munshi NC, Anderson KC, Treon SP


Blood Cancer Discovery

BCOR and BCORL1 Mutations Drive Epigenetic Reprogramming and Oncogenic Signaling by Unlinking PRC1.1 from Target Genes

Schaefer EJ, Wang HC, Karp HQ, Meyer CA, Cejas P, Fares I, Apffel A, Lim K, Xie Y, Gibson CJ, Schenone M, Murdock HM, Vedula RS, Winer ES, Garcia JS, Stone RM, Luskin MR, Carr SA, Long HW, Lindsley RC


British Journal of Cancer

CDH1 Germline Variants are Enriched in Patients with Colorectal Cancer, Gastric Cancer, and Breast Cancer

Adib E, El Zarif T, Nassar AH, Akl EW, Abou Alaiwi S, Rana HQ, Choueiri TK, Kwiatkowski DJ, Sonpavde G



Prevalence and Spectrum of Pathogenic Variants Among Patients with Multiple Primary Cancers Evaluated by Clinical Characteristics

Bychkovsky BL, Garber JE, Rana HQ



Spending Outcomes Among Patients with Cancer in Accountable Care Organizations 4 Years After Implementation

Erfani P, Phelan J, Orav EJ, Figueroa JF, Lam MB


Cancer Epidemiology, Biomarkers and Prevention

Cardiometabolic Risk in Childhood Cancer Survivors: A Report from the Children's Oncology Group

Lipshultz ER, Vrooman LM


Cancer Immunology Research

Linking a Trio of Molecular Features in Clear-Cell Renal Cell Carcinoma

Labaki C, Van Allen EM, Choueiri TK


Cancer Nursing

A Systematic Review and Meta-analytic Evaluation of Moral Distress in Oncology Nursing

Eche IJ, Phillips CS, Alcindor N, Mazzola E


Cancer Nursing

Exploring Clinicians' Perspectives of Barriers to Chemotherapy-Induced Peripheral Neuropathy Assessment and Management in Oncology Practice: A Qualitative Analysis of Semi-structured Interviews

Knoerl R, Wallar J, Fox E, Hong F, Salehi E, McCleary N, Ligibel JA, Reyes K


Cancer Treatment Reviews

Global Challenges and Policy Solutions in Breast Cancer Control

Trapani D, Fadelu T, Lin NU, Hassett M


Cell Research

The Hens Guarding Epithelial Cancer Fox-Houses

Gaynor LT, Shivdasani RA


Chemical Society Reviews

Small Molecule Modulation of Protein Polymerization

Fischer ES, Jones LH


Clinical Cancer Research

A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kb/d, in Patients with Advanced Solid Tumors

Choudhury AD, Shapiro GI


Clinical Cancer Research

Detecting Neuroendocrine Prostate Cancer Through Tissue-Informed Cell-Free DNA Methylation Analysis

Berchuck JE, Baca SC, McClure HM, Tsai HK, Nuzzo PV, Kelleher KM, He M, Steinharter JA, Zacharia S, Spisak S, Seo JH, Hirsch MS, Taplin ME, Choueiri TK, Pomerantz MM, Beltran H, Freedman ML


Clinical Cancer Research

From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit

Choueiri TK, Bakouny Z, Braun DA, Kaelin WG, Labaki C, McDermott DF, Pels K, Signoretti S


Clinical Nuclear Medicine

Radiation Recall Pneumonitis on FDG PET/CT Triggered by COVID-19 Vaccination

Hughes NM, Hammer MM, Awad MM, Jacene HA


Clinical Nuclear Medicine

Radiation Recall Pneumonitis on FDG PET/CT Triggered by COVID-19 Vaccination

Hughes NM, Hammer MM, Awad MM, Jacene HA


Current Opinion in Hematology

Venetoclax Combination Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndromes

Shimony S, Stone RM, Stahl M


Current Opinion in Oncology

Preoperative Immunotherapy for Head and Neck Cancers: State of Art

Egloff AM, Uppaluri R


Diabetology and Metabolic Syndrome

Metabolic Syndrome and Breast Cancer Survivors: A Follow-Up Analysis After Completion of Chemotherapy

Dieli-Conwright CM



How I Treat HER2-Positive Early Breast Cancer: How Long Adjuvant Trastuzumab is Needed?

Morganti S, Giordano A


European Journal of Cancer

Primary Results of STRONG: An Open-Label, Multicenter, Phase 3b Study of Fixed-Dose Durvalumab Monotherapy in Previously Treated Patients with Urinary Tract Carcinoma

Sonpavde GP


European Journal of Cancer

Serum Thymidine Kinase Activity in Patients with Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer Treated with Palbociclib and Fulvestrant

Tyekucheva S, Regan MM


Experimental Hematology

Transcriptional Differences Between JAK2-V617F and Wild-Type Bone Marrow Cells in Patients with Myeloproliferative Neoplasms/a>

Van Egeren D, Kamaz B, Liu S, Nguyen M, Reilly CR, DeAngelo DJ, Galinsky I, Wadleigh M, Winer ES, Luskin MR, Stone RM, Garcia JS, Hobbs GS, Michor F, Mullally A, Hormoz S


Head and Neck

Oligometastatic Adenoid Cystic Carcinoma: Correlating Tumor Burden and Time to Treatment with Outcomes

Tyan K, Bae JE, Lorch JH, Margalit DN, Tishler RB, Huynh MA, Jo VY, Haddad RI, Chau NG, Hanna GJ, Schoenfeld JD


International Journal of Cancer

Detection of Circulating Tumor Human Papillomavirus DNA Before Diagnosis of HPV-Positive Head and Neck Cancer

Rettig EM, Faden DL, Sandhu S, Wong K, Faquin WC, Warinner C, Richmon JD, Uppaluri R, Varvares M, Sethi R, Hanna GJ, Sroussi H


International Journal of Radiation Oncology, Biology, Physics

Dosimetric Planning Tradeoffs to Reduce Heart Dose Using Machine Learning-Guided Decision Support Software in Patients with Lung Cancer

Bitterman DS, Selesnick P, Bredfeldt J, Williams CL, Guthier C, Huynh E, Kozono DE, Cormack RA, Mak RH, Atkins KM


Journal of Clinical Neuroscience

Natural Language Processing for Automated Surveillance of Intraoperative Neuromonitoring in Spine Surgery

Agaronnik ND, Kwok A, Schoenfeld AJ, Lindvall C


Journal for ImmunoTherapy of Cancer

PI3K Activation Allows Immune Evasion by Promoting an Inhibitory Myeloid Tumor Microenvironment

Collins NB, Al Abosy R, Bi K, Yates KB, Manguso RT, Wadsworth M, Hughes T, Shalek AK, Boehm JS, Hahn WC, Doench JG


Journal for ImmunoTherapy of Cancer

Phase IB Study of Ziv-Aflibercept Plus Pembrolizumab in Patients with Advanced Solid Tumors

Rahma OE, Tyan K, Giobbie-Hurder A, Hathaway E, Cunningham R, Manos M, Severgnini M, Rodig S, Stephen Hodi F


Journal of Integrative and Complementary Medicine

Auricular Acupuncture During Chemotherapy Infusion in Breast Cancer Patients: A Feasibility Study

Yang E, Lu W, Giobbie-Hurder A, Chen WY, Block CC, Partridge A, Jeselsohn RM, Tolaney SM, Freedman RA, Ligibel JA


Journal of Neuroimaging

Imaging Features, Therapies, and Outcomes of Fibrosing Inflammatory Pseudotumor of the Nasopharynx: A Systematic Review

Mishra S, Bergmark RW, Jo VY, Miyawaki EK, Schoenfeld JD, Uppaluri R, Guenette JP


Journal of Pain and Symptom Management

One Size Doesn't Fit All in Early Pediatric Oncology Bereavement Support

Helton G, Beight L, Morris SE, Wolfe J, Snaman JM


Journal of Palliative Medicine

Missing Voices: Lessons Learned from Nonparticipating Caregivers in Palliative Care Research

Umaretiya PJ, Ilowite M, Fisher L, Mack JW, Bona K


Journal of Palliative Medicine

Top Ten Tips Palliative Care Clinicians Should Know About Psychedelic-Assisted Therapy in the Context of Serious Illness

Sager Z, Ljuslin M, Tulsky JA, Beaussant Y


Journal of Palliative Medicine

Top Ten Tips Palliative Care Clinicians Should Know About Psychedelic-Assisted Therapy in the Context of Serious Illness

Sager Z, Ljuslin M, Tulsky JA, Beaussant Y


Journal of Pediatric Hematology/Oncology

Large Anterior Mediastinal Mass and Cardiac Infiltration at Diagnosis in a Child With T-cell Acute Lymphoblastic Leukemia

Umaretiya P, Vrooman LM


Journal of Thoracic Oncology

Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status

Ricciuti B, Lin JJ, Vajdi A, Vokes N, Tolstorukov MY, Li YY, Spurr LF, Cherniack AD, Recondo G, Lamberti G, Wang X, Venkatraman D, Alessi JV, Vaz VR, Khosrowjerdi S, Digumarthy S, Park H, Vaz N, Nishino M, Sholl LM, Barbie D, Gainor JF, Awad MM


JAMA Network Open

Achieving Global Pediatric Palliative Care Equity-What We Have Yet to Learn

Umaretiya PJ, Wolfe J


JAMA Otolaryngology – Head and Neck Surgery

Use of Fluoro-[18F]-Deoxy-2-D-Glucose Positron Emission Tomography/Computed Tomography to Predict Immunotherapy Treatment Response in Patients with Squamous Cell Oral Cavity Cancers

Shah H, Wang Y, Cheng SC, Gunasti L, Chen YH, Lako A, Guenette J, Rodig S, Jo VY, Uppaluri R, Haddad R, Schoenfeld JD, Jacene HA


JCI Insight

Microbiota Dynamics in a Randomized Trial of Gut Decontamination During Allogeneic Hematopoietic Cell Transplantation

Li MM, Chen N, Duncan CN, Margossian SP, Lehmann LE, Birbrayer O, Silverstein S, Kim S, Ritz J, London WB, Whangbo JS


JCO Oncology Practice

Optimal Endocrine Therapy in Premenopausal Women: A Pragmatic Approach to Unanswered Questions

Sella T, Partridge AH


JCO Oncology Practice

Refining Patient-Centered Measures of End-of-Life Care Quality for Children with Cancer

Wolfe J


Leukemia and Lymphoma

Targeting Mitochondrial Metabolism in Acute Myeloid Leukemia

Stahl M



A T Cell Inflammatory Phenotype is Associated with Autoimmune Toxicity of the PI3K Inhibitor Duvelisib in Chronic Lymphocytic Leukemia

Gadi D, Griffith A, Tyekucheva S, Wang Z, Rai V, Vartanov A, Thrash E, Fernandes SM, Lehmberg TZ, Lee B, Martindale SP, Machado JH, Odejide O, Armand P, Fisher DC, Arnason J, Davids MS, Lederer JA, Brown JR


Medical Physics

Technical Note: Toward Implementation of MR-Guided Radiation Therapy for Laryngeal Cancer with Healthy Volunteer Imaging and a Custom MR-CT Larynx Phantom

Huynh E, Boyle S, Campbell J, Penney J, Mak RH, Schoenfeld JD, Leeman JE, Williams CL



Body CT and PET/CT Detection of Extracranial Lymphoma in Patients with Newly Diagnosed Central Nervous System Lymphoma

Nayak L, Batchelor TT, Huang RY, Guenette JP



Predictors of Long-Term Survival Among Patients with Brain Metastases

Lamba N, Catalano PJ, Bi WL, Wen PY, Haas-Kogan DA, Aizer AA


NPJ Breast Cancer

Impact of a Randomized Weight Loss Trial on Breast Tissue Markers in Breast Cancer Survivors

Dieli-Conwright CM


Pediatric Blood and Cancer

Pediatric Palliative Care has a Place Everywhere

Feraco AM


Pediatric Critical Care Medicine

Candidacy for Extracorporeal Life Support in Children After Hematopoietic Cell Transplantation: A Position Paper from the Pediatric Acute Lung Injury and Sepsis Investigators Network's Hematopoietic Cell Transplant and Cancer Immunotherapy Subgroup

Duncan C, Randolph AG, Lehmann L



Radiomics-based Cluster Groups to Predict Clinical-Pathologic and Genomic Characteristics of Stage I Lung Adenocarcinoma

Nishino M


Supportive Care in Cancer

Exploring the Impact of Exercise and Mind-Body Prehabilitation Interventions on Physical and Psychological Outcomes in Women Undergoing Breast Cancer Surgery

Knoerl R, Giobbie-Hurder A, Sannes TS, Dillon D, Dominici LS, Frank ES, Rhei E, Tolaney SM, Winer EP, Ligibel JA


Urologic Oncology

Prevalence of Pathogenic Germline Cancer Risk Variants in Testicular Cancer Patients: Identifying High Risk Groups

Nassar AH, Abou Alaiwi S, Adib E, Akl EW, Sonpavde GP


World Neurosurgery

Incidence and Predictors of Neurologic Death in Patients with Brain Metastases

Lamba N, Catalano PJ, Cagney DN, Wen PY, Aizer AA